Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLET" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"SITAGLIPTIN PHOSPHATE TABLET" OBTAINS APPROVAL FOR

DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Sitagliptin Phosphate Tablet", a drug used for glycemic control and developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of the Company, has obtained approval for drug registration granted by the National Medical Products Administration of the People's Republic of China. This product was filed as a Chemicals New Category 4 drug, and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has obtained approval for drug registration in China. With the recent successive approvals for launch of major products of the Group, our investment in research and development has started yielding fruitful results, and a series of products to be put on the market will continuously add momentum to the Group's rapid development.

Sitagliptin Phosphate Tablet is an effective and highly selective dipeptidyl peptidase-4（DPP-4）inhibitor, a new oral drug for controlling high blood sugar based on the incretin mechanism, and is used for improving glycemic control in adults with diabetes mellitus type 2. Clinical evidence shows that its efficacy in lowering blood sugar is positive, and it can be used alone with high safety and fair tolerance, without increasing the risk of hypoglycemia and causing gastrointestinal reactions; more importantly, it has long-term protection of β-cells in the pancreas, which can slow the progress of diabetes.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 28 February 2020

1

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2